Cocaine Dependence
Vaccines Forecast
Global cocaine use has climbed to an estimated 25 million people a year and US cocaine-involved overdose deaths have risen roughly six-fold since this report's original estimates, now increasingly driven by illicit fentanyl contamination rather than cocaine toxicity alone. No FDA-approved medication treats cocaine dependence, and the field's most clinically advanced vaccine candidate, TA-CD, stalled after disappointing Phase 2b efficacy more than a decade ago. This comprehensive commercial opportunity assessment draws on VacZine Analytics' long standing, independent authority in addiction vaccine markets to size the patient-based opportunity across the major seven markets, under two target product profiles.
- Format
- Executive presentation + Excel model
- Coverage
- Major seven markets
- TPPs
- Two, differing efficacy/administration
- Forecast horizon
- To 2035
- Approach
- Patient-based value/volume model
- Base edition
- 2020
- Availability
- Syndicated / bespoke
worldwide in the past year (UNODC)
cocaine in 2023, up 85% since 2019
that also involved opioids/fentanyl
cocaine use disorder
A fast-growing global market with no approved pharmacotherapy
Cocaine dependence sits in a genuinely underserved corner of addiction medicine: use is rising, the toxicology is worsening, and no medication has ever been approved for the underlying disorder. This review sets out the pharmacology, neurobiology and global burden before turning to the immunotherapy landscape now being assessed as one of the few mechanistically distinct treatment approaches.
Pharmacology and epidemiology - cocaine dependence
Cocaine is a naturally occurring tropane alkaloid, extracted from the leaves of the coca plant, that acts primarily by blocking the reuptake transporters for dopamine, noradrenaline and serotonin at the synapse. The resulting surge in synaptic dopamine, concentrated in the brain's mesolimbic reward pathway and nucleus accumbens, produces the short-lived euphoria and stimulant effects users seek, and it is this same dopaminergic flood that drives cocaine's high addictive liability and the compulsive, repeated use characteristic of cocaine use disorder. Chronic use remodels reward circuitry over time, blunting the brain's response to natural rewards and entrenching craving and relapse risk long after use stops, a neurobiological pattern that helps explain why behavioural treatment alone, while of proven benefit for some patients, leaves many others without an effective route to sustained abstinence.
The toxicology is equally significant. Cocaine's sympathomimetic action can precipitate acute cardiovascular events (myocardial infarction, arrhythmia, aortic dissection), cerebrovascular events, seizures and gastrointestinal ischaemia, and sudden cardiac death remains a recognised acute risk even in occasional users. The scale of use has grown substantially since this report's original estimates. Where the UNODC's 2009-era figures put global past-year cocaine use at 14.3 to 20.5 million people (0.3 to 0.5% of those aged 15 to 64), the UNODC's most recent World Drug Report puts global cocaine use at around 25 million people, up from 17 million a decade earlier, against a global prevalence of roughly 0.47%. Global cocaine production, seizures and use all reached new highs in the most recent reporting year, making cocaine, on the UNODC's own assessment, the world's fastest-growing illicit drug market by volume.
US mortality data tell a starker story still. Where cocaine was linked to around 5,100 deaths in the US in 2008, CDC data now attribute close to 30,000 overdose deaths a year to cocaine, roughly 28% of all US overdose deaths and an 85% rise since 2019 alone. Crucially, most of that increase is not cocaine toxicity in isolation: an estimated 79% of cocaine-involved overdose deaths also involve an opioid, overwhelmingly illicitly manufactured fentanyl, reflecting a supply increasingly contaminated with synthetic opioids rather than a simple rise in cocaine-only harm. That fentanyl-driven co-involvement is itself a significant part of the commercial case this report models: a cocaine-specific intervention that reduces use frequency or relapse also reduces a patient's exposure to an increasingly lethal, opioid-adulterated supply.
A stalled clinical history, and a pipeline that remains largely academic
Anti-cocaine immunotherapy has one of the longest and most difficult development histories in the addiction vaccine field. This report gives an honest account of where TA-CD's clinical programme stalled, and of the far earlier-stage academic work that has followed it, rather than overstating a pipeline that has, in reality, seen very little well-funded clinical activity in recent years.
-
Originally Xenova/Celtic PharmaStalled after Phase 2b, unapprovedTA-CD Succinylnorcocaine conjugated to cholera toxin B
The field's most clinically advanced candidate: succinylnorcocaine (a cocaine hapten) conjugated to the recombinant cholera toxin B subunit carrier protein, designed to raise anti-cocaine antibodies that sequester cocaine in the bloodstream before it reaches the brain. Developed by the UK's Xenova Group and later Celtic Pharma, TA-CD progressed further than any rival, but a multisite Phase 2b trial reported around 2009 to 2011 found efficacy was undermined by highly variable antibody titers between patients, with only a subset of vaccinated individuals reaching antibody levels sufficient to meaningfully blunt cocaine's effects. No further industry-sponsored development has followed, and TA-CD remains unapproved by any regulator as of the most recent published literature. -
Academic groups (US)Preclinical / early academicReformulated conjugate vaccines (e.g. dAd5GNE, hapten-fluorination approaches)
University-led programmes have continued to explore adenoviral-vectored and chemically modified cocaine-hapten conjugate vaccines aimed at raising more consistent, higher-titer antibody responses than TA-CD achieved, addressing the specific immunogenicity variability that undermined the earlier programme. This work remains at the preclinical and early academic stage rather than active human trials. -
Academic groups (US)Preclinical, passive immunotherapyAnti-cocaine monoclonal antibodies
A parallel, passive-immunisation approach uses a well-characterised monoclonal antibody, rather than a patient's own vaccine-induced response, to confer immediate, predictable anti-cocaine immunity, avoiding TA-CD's titer-variability problem by design. Humanised candidates such as GNCgzk have shown high affinity for cocaine in preclinical pharmacokinetic and cardiovascular-protection studies, but development remains academic and no candidate has yet entered human clinical trials. -
Academic groups (international)Preclinical, animal studiesNext-generation conjugate vaccines (e.g. COT-TT)
Published research as recently as 2025 has examined alternative hapten-carrier conjugates in animal models of cocaine-induced behavioural sensitisation, part of a continuing but modestly resourced academic effort to improve on TA-CD's immunogenicity rather than a sign of imminent clinical translation.
This has historically been a difficult, underfunded therapeutic area with limited big-pharma interest, and this report treats that honestly rather than overstating pipeline maturity. Unlike the opioid vaccine field, where a fentanyl-specific candidate entered human trials in 2026, no cocaine-specific vaccine or monoclonal antibody candidate is currently known to be in active human clinical trials; the most advanced work sits at the preclinical, university-led stage, more than a decade on from TA-CD's stalled Phase 2b. That very absence of pharmacotherapy, set against a growing, increasingly fentanyl-contaminated patient population, is itself central to the commercial case this report models: any candidate that resolves TA-CD's titer-consistency problem would be entering a market with no approved competition at all.
A wide-geography opportunity assessment across two target product profiles
This is a genuinely comprehensive report, sizing the patient-based commercial opportunity for a cocaine dependence vaccine across the major seven markets, under two differing target product profiles reflecting realistic efficacy and administration scenarios.
Patient-based value/volume demand modelling to 2035 across the major seven markets.
Full review of TA-CD's stalled clinical history and today's academic monoclonal antibody and conjugate vaccine research.
Differing efficacy and administration assumptions modelled side by side, reflecting realistic development scenarios.
Volume and value forecasts to 2035, built from epidemiological prevalence and treatment-seeking assumptions rather than top-down estimates.
Global burden review updated with current UNODC and CDC data, including fentanyl co-involvement trends in cocaine-related mortality.
Designed as an ideal tool to aid early-stage decision making in cocaine dependence vaccine positioning, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the geography and TPP framework. Full volume/value outputs, uptake assumptions and country-level data are in the licensed model.
| Geography | Target product profile | Patient segment | Status | Revenue scenario |
|---|---|---|---|---|
| United States | TPP1 - higher efficacy, clinic administered | Treatment-seeking cocaine use disorder | Modelled | Modelled |
| United States | TPP2 - moderate efficacy, primary care | Treatment-seeking cocaine use disorder | Modelled | Modelled |
| Major five EU markets | TPP1 / TPP2 | Treatment-seeking cocaine use disorder | Modelled | Modelled |
| █████ | ██████████ | ██████ | ██████ | $██m (base) |
| █████ | █████████ | ██████ | ██████ | $██m (upside) |
| Total addressable - base | All TPPs | All segments | All scenarios | $███m |
What you receive
A focused intelligence package combining a detailed summary presentation and one fully interactive forecast model, built for organisations evaluating a genuinely underserved corner of addiction medicine.
- Summary presentation - pharmacology, neurobiology, global burden, overdose mortality trends and full competitive/pipeline environment review
- Patient-based MS-Excel demand model - value/volume outputs to 2035 across the major seven markets
- Two target product profile scenarios - differing efficacy and administration assumptions modelled side by side
- Major seven markets coverage - each market modelled individually and in aggregate
- Competitor intelligence - TA-CD's stalled Phase 2b history and today's academic monoclonal antibody and conjugate vaccine research
- Updated epidemiology module - current UNODC global use and CDC overdose mortality data, including fentanyl co-involvement trends
- Early decision-making support - positioning and market entry guidance for a field with no approved competition
Built for organisations evaluating the cocaine dependence vaccine opportunity
Most valuable to teams assessing a difficult, historically underfunded therapeutic area against their own pipeline, BD ambitions or investment thesis, where no approved medication yet exists.
Vaccine & immunotherapy developers
Positioning and commercial feasibility assessment for anti-cocaine vaccine or monoclonal antibody candidates entering a market with no approved competition.
Corporate strategy & BD
Validate market structure and patient-based demand assumptions in a field where TA-CD's titer-variability problem has never been resolved.
Investors & analysts
Independent assessment of a historically underfunded field, now set against rapidly rising, increasingly fentanyl-contaminated cocaine mortality.
Public health & harm-reduction bodies
Burden and overdose-mortality modelling to support addiction treatment planning and harm-reduction resource allocation.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and addiction medicine planning.
Market access & policy
Pricing and access-pathway benchmarks for a treatment category that would enter Western reimbursement systems with no direct precedent.
VacZine Analytics has tracked addiction vaccine markets since our earliest editions, positioning us to assess a cocaine dependence vaccine opportunity that has been left largely unattended by major pharmaceutical R&D since TA-CD's clinical programme stalled. This is a very comprehensive report with a wide geographic focus across the major seven markets, and it has been well received by clients in the field for the depth of its pharmacology, epidemiology and competitive review. Few groups have followed this difficult, underfunded market as closely, and that recognised, independent expertise underpins everything in the analysis.
This report was last published as the 2020 edition; any refresh would incorporate current UNODC global use data, CDC overdose mortality trends including fentanyl co-involvement, and today's early-stage academic monoclonal antibody and conjugate vaccine research. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc cocaine dependence vaccine analysis, a briefing call is included on request.